AMPK inhibitor compound C suppresses cell proliferation by induction of apoptosis and autophagy in human colorectal cancer cells

Journal of Surgical Oncology

Volumn 106, Issue 6, 2012, Pages 680-688

  Yang, Weng Lang ^a   Perillo, William ^a   Liou, Deanna ^a   Marambaud, Philippe ^a   Wang, Ping ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

AMPK; apoptosis; autophagy; colorectal cancer; compound C

Indexed keywords

ACRIDINE ORANGE; ANTINEOPLASTIC AGENT; COMPOUND C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL ORGANELLE; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN CONDENSATION; COLORECTAL CANCER; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; HUMANS; PYRAZOLES; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867841791     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23184     Document Type: Article

References (53)

1. Fong Y, Salo J:, Surgical therapy of hepatic colorectal metastasis. Semin Oncol 1999; 26: 514-523.
2. Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
3. Giacchetti S, Perpoint B, Zidani R, et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
4. Grothey A, Sargent D, Goldberg RM, et al.: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
5. Grothey A, Ellis LM:, Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J 2006; 14: 170-177.
6. Baselga J:, The, EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 2001; 37: S16-S22.
7. Yang XD, Jia XC, Corvalan JR, et al.: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999; 59: 1236-1243.
8. Evans JM, Donnelly LA, Emslie-Smith AM, et al.: Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
9. Bowker SL, Majumdar SR, Veugelers P, et al.: Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258.
10. Zhou G, Myers R, Li Y, et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
11. Kemp BE, Mitchelhill KI, Stapleton D, et al.: Dealing with energy demand: The AMP-activated protein kinase. Trends Biochem Sci 1999; 24: 22-25.
12. Hardie DG:, The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci 2004; 117: 5479-5487.
13. Buzzai M, Jones RG, Amaravadi RK, et al.: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-6752.
14. Ben Sahra I, Laurent K, Loubat A, et al.: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-3586.
15. Zakikhani M, Dowling R, Fantus IG, et al.: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-10273.
16. Sullivan JE, Brocklehurst KJ, Marley AE, et al.: Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. FEBS Lett 1994; 353: 33-36.
17. Corton JM, Gillespie JG, Hawley SA, et al.: 5-aminoimidazole-4- carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells ? Eur J Biochem 1995; 229: 558-565.
18. Woodard J, Joshi S, Viollet B, et al.: AMPK as a therapeutic target in renal cell carcinoma. Cancer Biol Ther 2010; 10: 1168-1177.
19. Robert G, Ben Sahra I, Puissant A, et al.: Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PLoS One 2009; 18: e7889.
20. Guo D, Hildebrandt IJ, Prins RM, et al.: The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 2009; 106: 12932-12937.
21. Park HU, Suy S, Danner M, et al.: AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009; 8: 733-741.
22. Jin J, Mullen TD, Hou Q, et al.: AMPK inhibitor Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. J Lipid Res 2009; 50: 2389-2397.
23. Baumann P, Mandl-Weber S, Emmerich B, et al.: Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells. Anticancer Drugs 2007; 18: 405-410.
24. Vucicevic L, Misirkic M, Janjetovic K, et al.: AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol 2009; 77: 1684-1693.
25. Kim HS, Hwang JT, Yun H, et al.: Inhibition of AMP-activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. J Biol Chem 2008; 283: 3731-3742.
26. Jang JH, Lee TJ, Yang ES, et al.: Compound C sensitizes Caki renal cancer cells to TRAIL-induced apoptosis through reactive oxygen species-mediated down-regulation of c-FLIPL and Mcl-1. Exp Cell Res 2010; 316: 2194-2203.
27. Jung SN, Park IJ, Kim MJ, et al.: Down-regulation of AMP-activated protein kinase sensitizes DU145 carcinoma to Fas-induced apoptosis via c-FLIP degradation. Exp Cell Res 2009; 315: 2433-2441.
28. Ahn HJ, Kim YS, Kim JU, et al.: Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. J Cell Biochem 2004; 91: 1043-1052.
29. Paglin S, Hollister T, Delohery T, et al.: A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 2001; 61: 439-444.
30. Mizushima N, Yoshimori T:, How to interpret LC3 immunoblotting. Autophagy 2007; 3: 542-545.
31. Vousden KH, Lane DP:, p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-283.
32. Cheung CH, Cheng L, Chang KY, et al.: Investigations of survivin: The past, present and future. Front Biosci 2011; 16: 952-961.
33. Rochette PJ, Bastien N, Lavoie J, et al.: SW480, a p53 double-mutant cell line retains proficiency for some p53 functions. J Mol Biol 2005; 352: 44-57.
34. Fujiwara K, Daido S, Yamamoto A, et al.: Pivotal role of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in apoptosis and autophagy. J Biol Chem 2008; 283: 388-397.
35. Ha J, Daniel S, Broyles SS, et al.: Critical phosphorylation sites for acetyl-CoA carboxylase activity. J Biol Chem 1994; 269: 22162-22168.
36. Warburg O:, Metabolism of tumours. Biochem Zeitschr 1923; 142: 317-333.
37. Kroemer G, Pouyssegur J:, Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 2008; 13: 472-482.
38. Laderoute KR, Amin K, Calaoagan JM, et al.: 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 2006; 26: 5336-5347.
39. Shackelford DB, Shaw RJ:, The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-575.
40. Wang W, Guan KL:, AMP-activated protein kinase and cancer. Acta Physiol 2009; 196: 55-63.
41. Johnson DG, Walker CL:, Cyclins and cell cycle check-points. Annu Rev Pharmacol Toxicol 1999; 39: 295-312.
42. Vucicevic L, Misirkic M, Janjetovic K, et al.: Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. Autophagy 2011; 7: 40-50.
43. Mizushima N, Levine B, Cuervo AM, et al.: Autophagy fights disease through cellular self-digestion. Nature 2008; 451: 1069-1075.
44. White E:, Autophagic cell death unraveled: Pharmacological inhibition of apoptosis and autophagy enables necrosis. Autophagy 2008; 4: 399-401.
45. Galluzzi L, Vicencio JM, Kepp O, et al.: To die or not to die: That is the autophagic question. Curr Mol Med 2008; 8: 78-91.
46. Maiuri MC, Galluzzi L, Morselli E, et al.: Autophagy regulation by p53. Curr Opin Cell Biol 2010; 22: 181-185.
47. Morselli E, Tasdemir E, Maiuri MC, et al.: Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 2008; 7: 3056-3061.
48. Ambrosini G, Adida C, Altieri DC:, A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
49. Roca H, Varsos Z, Pienta KJ:, CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem 2008; 283: 25057-25073.
50. Chiou SK, Hoa N, Hodges A:, Sulindac sulfide induces autophagic death in gastric epithelial cells via Survivin down-regulation: A mechanism of NSAIDs-induced gastric injury. Biochem Pharmacol 2011; 81: 1317-1323.
51. Lens SM, Vader G, Medema RH:, The casefor survivinas mitotic regulator. Curr Opin Cell Biol 2006; 18: 616-622.
52. Zhonghong L, Lianjie L, Changqing Z, et al.: The influence of survivin shRNA on the cell cycle and the invasion of SW480 cells of colorectal carcinoma. J Exp Clin Cancer Res 2008; 27: 20.
53. Lechler P, Renkawitz T, Campean V, et al.: The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro. BMC Cancer 2011; 11: 120.